Last reviewed · How we verify
NCT06295367
Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)
NA trial testing Best Practice in Malignant Solid Neoplasm in 760 participants. Currently enrolling.
1 December 2027
Quick facts
| Lead sponsor | ECOG-ACRIN Cancer Research Group |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 760 |
| Start date | 29 February 2024 |
| Primary completion | 1 December 2027 |
| Estimated completion | 1 December 2027 |
| Sites | 181 locations across Puerto Rico, United States |
Drugs / interventions tested
- Best Practice
- Financial Navigation
- Interview
- Survey Administration
Conditions studied
- Malignant Solid Neoplasm — all drugs for Malignant Solid Neoplasm →
Sponsor
ECOG-ACRIN Cancer Research Group
Who can join
Eligibility, any sex, with Malignant Solid Neoplasm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This clinical trial evaluates the effect of Cost Communication and Financial Navigation (CostCOM) intervention on adherence to care and financial burden in cancer patients. Many cancer patients experience financial hardship due to high medical out of pocket costs (OOPC), changes in employment, income and insurance. Financial hardship can lead to a delay or a stop in cancer care, and is linked to poor quality of life. Financial navigation programs, such as CostCOM, provide financial counseling, education and connections to appropriate resources to reduce financial barriers to healthcare and minimize financial stress and burden. CostCOM may improve adherence to care and decrease financial burden in patients with cancer.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Interventions to Address Cancer-Related Financial Hardship: A Scoping Review and Call to Action.
Wheeler SB, Thom B, Waters AR, Shankaran V. · · 2025 · cited 20× · PMID 39793544 · DOI 10.1200/op.24.00375 -
Effectiveness of out-of-pocket cost COMmunication and financial navigation (CostCOM) in cancer patients: Study protocol for ECOG-ACRIN EAQ222CD.
Sadigh G, Duan F, Gareen IF, Hancock J, et al · · 2025 · PMID 40147544 · DOI 10.1016/j.cct.2025.107889
Verify or expand the search:
- PubMed search for NCT06295367
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Best Practice
Trials testing the same drug.
- NCT07126548 — A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men · NA · not yet recruiting
- NCT07022678 — Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia · Phase 3 · not yet recruiting
- NCT07225855 — Geriatric Assessment and Management for Older Adults Undergoing Chemotherapy and Radiation Therapy for Head and Neck Can · NA · not yet recruiting
- NCT05874297 — Online Nutrition Education to Decrease the Side Effects of Chemotherapy in Patients With Breast Cancer · NA · not yet recruiting
- NCT07176000 — Tailored Patient Navigation to Improve the Uptake of Lung Cancer Screening in Tribal Communities in Western Washington S · NA · not yet recruiting
Other recruiting trials for Malignant Solid Neoplasm
Currently open trials in the same condition.
- NCT06202066 — Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuro · Phase 2 · recruiting
- NCT06565260 — Community-Based Exercise and Nutrition Training and Education Program for Cancer Survivors · NA · recruiting
- NCT07220447 — L-Theanine to Support Relaxation and Mood for Cancer Patients in Surveillance · EARLY_PHASE1 · recruiting
- NCT07365007 — A Virtually Delivered Diet Intervention (LASO-3) for the Improvement of Chemotherapy-Induced Peripheral Neuropathy in Ca · NA · recruiting
- NCT07477886 — Ambient Sensing Room to Detect Early Signs of Adverse Events in Hospitalized Patients With Cancer · recruiting
Other ECOG-ACRIN Cancer Research Group trials
Trials by the same sponsor.
- NCT07001748 — Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With G · Phase 2, PHASE3 · recruiting
- NCT06526897 — Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Ext · NA · not yet recruiting
- NCT06475989 — Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer · Phase 3 · recruiting
- NCT06084845 — Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for P · Phase 2 · withdrawn
- NCT06319027 — Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Tr · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06295367 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by ECOG-ACRIN Cancer Research Group
- Last refreshed: 3 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06295367.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing